Indication
Viral hepatitis A prevention
Viral hepatitis A prevention refers to pre-exposure prophylaxis or post-exposure immunization against infection caused by the hepatitis A virus (HAV), an enterically transmitted picornavirus that targets the hepatic system. Read more about Viral hepatitis A prevention
4 drugs 1 manufacturers
Drugs that treat it
Common Viral hepatitis A prevention therapies.
GAMASTAN (immune globulin,gamma(IgG)/glycine)
GAMASTAN S-D (immune globulin,gamma(IgG)/glycine)
GAMASTAN S/D (immune globulin,gamma(IgG)/glycine)
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonViral hepatitis A prevention refers to pre-exposure prophylaxis or post-exposure immunization against infection caused by the hepatitis A virus (HAV), an enterically transmitted picornavirus that targets the hepatic system.
Transmission primarily occurs via the fecal-oral route through direct contact with an infectious person or ingestion of contaminated food or water, placing non-immune children, travelers to endemic areas, and populations experiencing homelessness or substance use at heightened risk.
Pathophysiologically, HAV replication in hepatocytes triggers immune-mediated hepatocellular injury, clinically manifesting as an acute, self-limited illness characterized by fever, malaise, nausea, right upper quadrant abdominal pain, dark urine, and jaundice.
Prophylaxis aims to avert symptomatic acute hepatitis, prolonged cholestasis, and rare complications such as fulminant hepatic failure in susceptible individuals.
- cdc.gov
Viral hepatitis A prevention refers to pre-exposure prophylaxis or post-exposure immunization against infection caused by the hepatitis A virus (HAV), an enterically transmitted picornavirus that targets the hepatic system
- cdc.gov
Viral hepatitis A prevention refers to pre-exposure prophylaxis or post-exposure immunization against infection caused by the hepatitis A virus (HAV), an enterically transmitted picornavirus that targets the hepatic system Transmission primarily occurs via the fecal-oral route through direct contact with an infectious person or ingestion of contaminated food or water, placing non-immune children, travelers to endemic areas, and populations experiencing homelessness or substance use at heightened...
- fda.gov
Pathophysiologically, HAV replication in hepatocytes triggers immune-mediated hepatocellular injury, clinically manifesting as an acute, self-limited illness characterized by fever, malaise, nausea, right upper quadrant abdominal pain, dark urine, and jaundice Prophylaxis aims to avert symptomatic acute hepatitis, prolonged cholestasis, and rare complications such as fulminant hepatic failure in susceptible individuals
Personalize your experience
Follow Viral hepatitis A prevention and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.